Mittelschmerz (German for "middle pain") is a benign, self-limited, physiologic mid-cycle pelvic pain occurring around the time of ovulation, approximately day 14 of a 28-day menstrual cycle. It is classified under ICD-10 code N94.0. [1] The pain results from the physiological trauma of follicular rupture and release of follicular fluid and blood into the peritoneal cavity. [2-3] Ultrasonography has demonstrated small quantities of free pelvic fluid in ~40% of cycles at mid-cycle, with two-thirds of painful cycles showing sonographic fluid at ovulation. [2]
1. History
- Location: Unilateral lower abdominal/pelvic pain; may alternate sides month to month depending on which ovary ovulates
- Timing: Occurs at mid-cycle (approximately days 12–16), correlating with the LH surge and ovulation [4]
- Duration: Typically lasts hours to 1–2 days; rarely beyond 48 hours
- Character: Dull, crampy, or sharp; ranges from mild twinge to moderate discomfort
- Associated symptoms: Mild spotting or intermenstrual bleeding may occur; some patients report bloating, breast tenderness (postovulatory), or low backache [4]
- Important negatives: No fever, no vaginal discharge, no progressive worsening, no hemodynamic instability
- Key question: "Does this pain recur predictably at mid-cycle, approximately 2 weeks before your next expected period?"
2. Alarm Features
- Severe or worsening pain beyond 48 hours
- Hemodynamic instability (tachycardia, hypotension) → consider ruptured hemorrhagic ovarian cyst or ectopic pregnancy
- Positive pregnancy test → must rule out ectopic pregnancy [5-6]
- Fever, chills, vaginal discharge → consider PID or tubo-ovarian abscess [5]
- Nausea/vomiting with acute severe pain → consider ovarian torsion (localized pain OR 4.36, vomiting OR 2.38) [7]
- Peritoneal signs (rebound, guarding) → surgical abdomen workup required
- Pain at McBurney's point or positive Rovsing sign → appendicitis [5]
3. Medications
- First-line treatment: NSAIDs (ibuprofen 400–800 mg q8h or naproxen 250–500 mg q12h) for symptomatic relief [8]
- Suppressive therapy: Combined oral contraceptives (COCs) suppress ovulation and eliminate mittelschmerz; continuous monophasic regimens may be more effective [8]
- Alternative hormonal options: Progestin-only pills, depot medroxyprogesterone, levonorgestrel IUD, or etonogestrel implant — all suppress ovulation to varying degrees [8]
- Special populations: In patients with bleeding diatheses (e.g., von Willebrand disease), mid-cycle tranexamic acid has been reported to reduce ovulation-associated pain from hemorrhagic cysts [9]
- Avoid: Opioids are not indicated for this benign condition
4. Diet
- No specific dietary triggers or restrictions
- Anti-inflammatory dietary patterns (omega-3 fatty acids, fruits, vegetables) may modestly reduce pelvic pain in general, though evidence is insufficient to recommend specific supplements for mittelschmerz [8]
- Adequate hydration is reasonable general advice
5. Review of Systems
- GYN: Menstrual regularity, last menstrual period, intermenstrual bleeding, vaginal discharge, dyspareunia, dysmenorrhea
- GI: Nausea, vomiting, diarrhea, constipation, anorexia (to differentiate from appendicitis, diverticulitis)
- GU: Dysuria, frequency, hematuria (to rule out UTI/urolithiasis)
- Constitutional: Fever, weight loss (red flags for infection or malignancy)
- Reproductive: Sexual activity, contraception use, fertility goals
6. Collateral History and Family History
- Family history of endometriosis (most common cause of secondary dysmenorrhea) [10]
- Family history of ovarian cysts or polycystic ovarian syndrome
- History of bleeding disorders (e.g., von Willebrand disease) — may exacerbate hemorrhagic cyst formation and worsen mittelschmerz [9]
- Social context: Fertility awareness — some patients use mittelschmerz as a marker for natural family planning [4]
7. Risk Factors
- Ovulatory cycles — mittelschmerz only occurs in ovulating patients; anovulatory patients (on hormonal contraception, postmenopausal) do not experience it
- More commonly recognized in patients who track their cycles closely
- Bleeding diatheses may increase severity due to greater peritoneal hemorrhage at ovulation [9]
- No clear association with parity, age at menarche, or BMI
8. Differential Diagnosis
This is the critical section for ED and primary care evaluation. Mittelschmerz is a diagnosis of exclusion — dangerous mimics must be ruled out first. [5]
Cannot-miss diagnoses
- Ectopic pregnancy — responsible for 6% of maternal deaths; 40% misdiagnosed at initial visit; always obtain pregnancy test [6]
- Ovarian torsion — sudden severe unilateral pain with nausea/vomiting; enlarged ovary on ultrasound [7][11]
- Ruptured hemorrhagic ovarian cyst — sudden onset, may cause hemoperitoneum
- Appendicitis — RLQ pain, anorexia, migration from periumbilical area; most common abdominal surgical emergency [5]
Other important differentials
- Pelvic inflammatory disease — bilateral pain, cervical motion tenderness, discharge [5]
- Endometriosis — cyclic pain but typically perimenstrual, dyspareunia, infertility [10]
- Urolithiasis — colicky flank/groin pain, hematuria
- UTI/pyelonephritis — dysuria, frequency, CVA tenderness
Distinguishing features of mittelschmerz: Predictable mid-cycle timing, self-limited (<48 hours), mild-moderate severity, no systemic symptoms, negative pregnancy test, normal vitals.
9. Past Medical History
- Prior episodes of similar mid-cycle pain (recurrence is characteristic)
- History of ovarian cysts or hemorrhagic cysts
- Endometriosis or prior pelvic surgery (adhesions)
- Bleeding disorders
- Prior ectopic pregnancy or PID (increases risk of ectopic)
10. Physical Exam
- Vital signs: Should be normal; tachycardia or hypotension is a red flag
- Abdominal exam: Mild unilateral lower quadrant tenderness; no peritoneal signs (rebound, guarding)
- Carnett sign: Negative (pain does not worsen with abdominal wall contraction) — helps exclude abdominal wall pathology [5]
- Pelvic exam (if indicated): No cervical motion tenderness, no adnexal masses, no mucopurulent discharge; mild unilateral adnexal tenderness may be present
- Expected findings: Benign exam with mild focal tenderness only
11. Lab Studies
- Urine pregnancy test (β-hCG): Mandatory in all reproductive-age patients with pelvic pain — the single most important initial test [5][12]
- CBC: If concern for hemorrhagic cyst, torsion, or appendicitis; should be normal in mittelschmerz
- Urinalysis: To exclude UTI/urolithiasis
- STI screening (GC/chlamydia): If PID is in the differential
- No labs are required if the clinical picture is classic and pregnancy is excluded
12. Imaging
- Not routinely needed for classic mittelschmerz with a reassuring history and exam
- Transvaginal ultrasound is the first-line imaging modality when the diagnosis is uncertain: [5][12]
- May show a small amount of free pelvic fluid (physiologic at ovulation) [2]
- May show a dominant follicle or corpus luteum
- Rules out hemorrhagic cyst, ovarian torsion, ectopic pregnancy, adnexal mass
- CT abdomen/pelvis: Reserved for suspected non-gynecologic etiologies (appendicitis, urolithiasis) [5]
- MRI: Second-line if ultrasound and CT are nondiagnostic [13]
13. Special Tests
- No specific diagnostic test confirms mittelschmerz — it is a clinical diagnosis based on characteristic timing and exclusion of pathology
- Basal body temperature charting or ovulation predictor kits can help correlate pain with ovulation timing
- Point-of-care ultrasound (POCUS): Useful in the ED to rapidly assess for free fluid, adnexal masses, and intrauterine pregnancy
14. ECG
15. Assessment
Mittelschmerz is a benign physiologic phenomenon reflecting normal ovulation. [2-3] It is a clinical diagnosis made when:
- Pain is unilateral, mid-cycle, and self-limited (<48 hours)
- Pregnancy test is negative
- No alarm features are present
- Physical exam is benign
Severity is typically mild to moderate. Atypical presentations (severe pain, prolonged duration, systemic symptoms) should prompt further workup to exclude dangerous pathology. In patients with underlying bleeding disorders, ovulation-associated hemorrhagic cysts may cause more severe symptoms. [9]
16. Treatment Plan
Acute management
- Reassurance — the most important intervention; educate that this is normal physiology
- NSAIDs: Ibuprofen 400–800 mg q8h PRN or naproxen 250–500 mg q12h PRN for 1–2 days [8]
- Heat therapy: Topical heat application to the lower abdomen [8]
Recurrent/bothersome mittelschmerz
- Combined oral contraceptives (continuous or cyclic) — suppress ovulation and eliminate the pain [8]
- Other hormonal options: Depot medroxyprogesterone, levonorgestrel IUD, etonogestrel implant [8]
- Choice of hormonal method should factor in the patient's contraceptive needs and fertility goals
No surgical intervention is indicated for mittelschmerz.
17. Disposition
- Discharge: The vast majority of patients can be safely discharged from the ED or managed in the outpatient setting
- Observation: Consider if pain is atypical, workup is pending, or diagnosis is uncertain
- Admission criteria: Hemodynamic instability, peritoneal signs, concern for surgical pathology (torsion, ruptured ectopic, appendicitis)
- Specialist consultation: OB/GYN referral if recurrent severe episodes unresponsive to NSAIDs/hormonal therapy, or if workup reveals ovarian pathology
18. Follow Up / Return Precautions
- Follow-up: Routine follow-up with PCP or OB/GYN if symptoms are recurrent and bothersome; no urgent follow-up needed for a single classic episode
- Return precautions — counsel patients to return immediately for:
- Worsening or persistent pain beyond 2–3 days
- Fever or chills
- Heavy vaginal bleeding
- Dizziness, lightheadedness, or fainting
- Missed period or positive pregnancy test
- Expected recovery: Pain typically resolves spontaneously within hours to 1–2 days
- Counseling: Encourage menstrual cycle tracking to identify the pattern; discuss hormonal suppression if episodes significantly impact quality of life
References
1. CMS.gov: N94-Pain and oth cond assoc w fem gntl org and menstrual cycle. — Centers for Medicare & Medicaid Services (CMS) and the National Center for Health Statistics 2024.
2. Mittelschmerz. Sonographic Demonstration. — Hann LE, Hall DA, Black EB, Ferrucci JT. The Journal of the American Medical Association. 1979.
3. Cyclic Pelvic Pain. — Muse KN. Obstetrics and Gynecology Clinics of North America. 1990.
4. Natural Family Planning III. Intermenstrual Symptoms and Estimated Time of Ovulation. — Hilgers TW, Daly KD, Prebil AM, Hilgers SK. Obstetrics and Gynecology. 1981.
5. Evaluation of Acute Pelvic Pain in Women. — Frasca DJ, Jarrio CE, Perdue J. American Family Physician. 2023.
6. Does This Woman Have an Ectopic Pregnancy?The Rational Clinical Examination Systematic Review. — Crochet JR, Bastian LA, Chireau MV. The Journal of the American Medical Association. 2013.
7. Identifying Reliable Predictors of Ovarian Torsion in Acute Gynecological Presentations: A Retrospective Case-Control Study. — Aiob A, Shushan Marom SB, Gumin D, Lowenstein L, Sharon A. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2025.
8. Dysmenorrhea. — McKenna KA, Fogleman CD. American Family Physician. 2021.
9. Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient With Type 1 Von Willebrand Disease and Recurrent Hemorrhagic Cysts. — Lasry A, Gil Y, Balayla J. Journal of Obstetrics and Gynaecology Canada : JOGC = Journal d'Obstetrique Et Gynecologie Du Canada : JOGC. 2020.
10. Endometriosis: Evaluation and Treatment. — Edi R, Cheng T. American Family Physician. 2022.
11. Adnexal Torsion in Adolescents: ACOG Committee Opinion No, 783. — Committee on Adolescent Health Care Obstetrics and Gynecology. 2019.
12. ACR Appropriateness Criteria® Acute Pelvic Pain in the Reproductive Age Group: 2023 Update. — Brook OR, Dadour JR, Robbins JB, et al. Journal of the American College of Radiology : JACR. 2024.
13. ESR Essentials: Gynaecological Causes of Acute Pelvic Pain in Women: A Primer for Emergent Evaluation-Practice Recommendations by the European Society of Emergency Radiology. — Dick EA, Blanco A, De La Hoz Polo M, Basilico R. European Radiology. 2025.